Spots Global Cancer Trial Database for relapsed non hodgkin lymphoma
Every month we try and update this database with for relapsed non hodgkin lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) | NCT03938987 | Relapsed Non Ho... Relapsed Adult ... Relapsed Pediat... | autologous CD19... | 2 Years - 70 Years | University of Alberta | |
| Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT03719989 | Diffuse Large B... Relapsed Non Ho... Refractory Non-... | azacitidine plu... | 19 Years - 75 Years | Seoul National University Hospital | |
| CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | NCT03774654 | Refractory B-Ce... Refractory B-Ce... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... | CD19.CAR-aNKT c... | 3 Years - 75 Years | Baylor College of Medicine | |
| Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) | NCT03938987 | Relapsed Non Ho... Relapsed Adult ... Relapsed Pediat... | autologous CD19... | 2 Years - 70 Years | University of Alberta | |
| Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma | NCT03505944 | Relapsed Non Ho... | Venetoclax | 19 Years - | Nordic Lymphoma Group | |
| Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma | NCT03505944 | Relapsed Non Ho... | Venetoclax | 19 Years - | Nordic Lymphoma Group | |
| A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity | NCT04150913 | Non Hodgkin Lym... Refractory Non-... Relapsed Non Ho... Neurotoxicity Neurotoxicity S... Cytokine Releas... | Anakinra Axicabtagene Ci... | 18 Years - | Massachusetts General Hospital | |
| Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL | NCT03042585 | Relapsed Non Ho... Refractory Non-... | Total body irra... | 18 Years - | Loyola University | |
| Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma | NCT05006534 | Relapsed Non Ho... Refractory Lymp... | 20 Years - | National Taiwan University Hospital | ||
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | NCT03091933 | Hematologic Can... Relapse Leukemi... Relapsed Adult ... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... Relapsed Hodgki... Relapsed Myelod... Relapsed Multip... | GLIDE | 18 Years - 65 Years | Ciusss de L'Est de l'Île de Montréal | |
| Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT03719989 | Diffuse Large B... Relapsed Non Ho... Refractory Non-... | azacitidine plu... | 19 Years - 75 Years | Seoul National University Hospital | |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | NCT03091933 | Hematologic Can... Relapse Leukemi... Relapsed Adult ... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... Relapsed Hodgki... Relapsed Myelod... Relapsed Multip... | GLIDE | 18 Years - 65 Years | Ciusss de L'Est de l'Île de Montréal | |
| CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | NCT05260957 | Refractory Non-... Relapsed Non Ho... Aggressive Non-... | Mosunetuzumab Polatuzumab CAR-T Cell Ther... | 18 Years - 80 Years | University of Miami | |
| A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma | NCT04923789 | Relapsed Non Ho... Refractory Non-... | 18 Years - 65 Years | The First Affiliated Hospital of Soochow University | ||
| A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma | NCT04923789 | Relapsed Non Ho... Refractory Non-... | 18 Years - 65 Years | The First Affiliated Hospital of Soochow University | ||
| Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma | NCT05053659 | Relapsed Non Ho... Refractory Non-... | Loncastuximab t... Venetoclax | 18 Years - | Case Comprehensive Cancer Center | |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | NCT04978779 | Relapsed Non Ho... Chronic Lymphoc... Refractory Chro... Richter Syndrom... MYC Amplificati... MYC Overexpress... MYC Translocati... | VIP152 BTKi | 18 Years - | Vincerx Pharma, Inc. | |
| Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL | NCT03042585 | Relapsed Non Ho... Refractory Non-... | Total body irra... | 18 Years - | Loyola University | |
| Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma | NCT05053659 | Relapsed Non Ho... Refractory Non-... | Loncastuximab t... Venetoclax | 18 Years - | Case Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
